| Title |
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, April 2013
|
| DOI | 10.2147/dmso.s43403 |
| Pubmed ID | |
| Authors |
Jin Hee Shin, Kishore M Gadde |
| Abstract |
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Netherlands | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 103 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Unknown | 101 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 15% |
| Student > Ph. D. Student | 13 | 13% |
| Student > Master | 11 | 11% |
| Student > Bachelor | 11 | 11% |
| Other | 8 | 8% |
| Other | 23 | 22% |
| Unknown | 22 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 31% |
| Agricultural and Biological Sciences | 14 | 14% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Neuroscience | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 13 | 13% |
| Unknown | 31 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2022.
All research outputs
#2,087,479
of 25,457,858 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#95
of 1,184 outputs
Outputs of similar age
#16,864
of 213,192 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#1
of 5 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,192 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them